Aytu BioPharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AYTU research report →
Companyaytubio.com
Aytu Biopharma, Inc. , a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.
- CEO
- Joshua R. Disbrow
- IPO
- 2008
- Employees
- 102
- HQ
- Englewood, CO, US
Price Chart
Valuation
- Market Cap
- $17.41M
- P/E
- -0.66
- P/S
- 0.31
- P/B
- 0.64
- EV/EBITDA
- -0.52
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 62.50%
- Op Margin
- -26.79%
- Net Margin
- -60.17%
- ROE
- -148.91%
- ROIC
- -23.62%
Growth & Income
- Revenue
- $66.38M · 1.84%
- Net Income
- $-13,562,000 · 14.40%
- EPS
- $-2.16 · 24.48%
- Op Income
- $-7,827,000
- FCF YoY
- -200.82%
Performance & Tape
- 52W High
- $3.07
- 52W Low
- $1.46
- 50D MA
- $2.54
- 200D MA
- $2.39
- Beta
- 0.28
- Avg Volume
- 47.48K
Get TickerSpark's AI analysis on AYTU
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 25 | DOCKERY CARL | other | 0 |
| Oct 3, 25 | PYSZCZYMUKA GREG | other | 12,500 |
| Oct 3, 25 | Disbrow Jarrett | other | 12,500 |
| Oct 3, 25 | Disbrow Jarrett | other | 19,606 |
| Oct 3, 25 | Selhorn Ryan J | other | 17,500 |
| Oct 3, 25 | Selhorn Ryan J | other | 16,243 |
| Oct 3, 25 | Disbrow Joshua R. | other | 22,500 |
| Oct 3, 25 | Disbrow Joshua R. | other | 31,446 |
| Oct 3, 25 | LIU VIVIAN H | other | 10,000 |
| Oct 3, 25 | JAIN ABHINAV | other | 10,000 |
Our AYTU Coverage
We haven't published any research on AYTU yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AYTU Report →